Certara
CERT · NASDAQ · Healthcare
$8.42
$0.16 (-1.86%) today
Market Cap
$1.28B
24h Volume
$56.2M
P/E Ratio
0.0
52w High
$13.60
52w Low
$4.48
Est. AI Revenue
30%
7-Day Sparkline (Static)
Company facts
Performance
About Certara
Certara sells biosimulation software and services that let drug developers model how medicines behave in the body before and alongside clinical trials. Pharmaceutical and biotech companies pay software subscriptions and consulting fees for model-informed drug development that can reduce trial size and speed regulatory approval.
Its products include the Simcyp simulator for predicting drug behavior in virtual patient populations, Phoenix for pharmacokinetic analysis, and Pinnacle 21 for regulatory data preparation. The Certara.AI platform applies generative AI and large language models to regulatory writing and drug development modeling, and the company counts most of the top 20 global pharma companies as customers.
Founded in 2008 and headquartered in Radnor, Pennsylvania, Certara employs about 1,500 people and trades on the NASDAQ. Jon Resnick became chief executive in January 2026.
Certara in the AI buildout
Certara sits in the AI Healthcare layer and the AI Applications layer. It sells the modeling software that pharma companies use to simulate drugs instead of testing everything in humans, and its Certara.AI platform brings generative AI into regulatory writing and trial design. As drug developers adopt AI to compress timelines, Certara is one of the established vendors positioned to monetize that shift through subscriptions, sitting between raw AI models and the regulated workflows of drug approval.
CERT is tracked in AI Healthcare and AI Applications, rated Growing on the AI Exposure leaderboard.
By the numbers
52-week range
CERT trades at $8.42, 43% of the way up its 52-week range of $4.48 to $13.60.
Market cap
Market capitalization is $1.28B, with an AI Exposure Score of 48 out of 100.
Next earnings
Certara is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Certara do?
Certara makes biosimulation software that models how drugs behave in the body, helping pharmaceutical companies design better trials and win regulatory approval faster. It earns revenue from software subscriptions and related consulting services for drug developers worldwide.
How is Certara exposed to AI?
Supercycle rates Certara as Growing with an AI Exposure Score of 48 out of 100. Simulation and machine learning are core to its products, but much of the business is classical modeling and services, with the generative AI layer still expanding.
What are Certara's main products?
Simcyp simulates drug behavior in virtual patient populations, Phoenix handles pharmacokinetic analysis, and Pinnacle 21 prepares regulatory data. Certara.AI adds generative AI and large language models for regulatory writing and drug development modeling.
Who leads Certara?
Jon Resnick became chief executive on January 1, 2026, succeeding William Feehery. Resnick joined from IQVIA, where he spent more than two decades and most recently led the US and Canada region.
Is CERT a pure play AI stock?
No. Certara is a Growing tier stock. Its biosimulation business predates modern AI and includes substantial services work, but the Certara.AI platform gives it a genuine and growing generative AI product line inside pharma workflows.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.